15d-PGJ2 reduced microglia activation and alleviated neurological deficit of ischemic reperfusion in diabetic rat model

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Huang, Lihong ^a   Li, Gang ^b   Feng, Xiaofang ^a   Wang, Luojun ^a  

^a Central Hospital of Zhabei District   (China)

^b TONGJI UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

15D PGJ 2; CHLORDANE; INTERLEUKIN 1; NEUROPROTECTIVE AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; STREPTOZOCIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; 15-DEOXYPROSTAGLANDIN J2; CD68 PROTEIN, RAT; DIFFERENTIATION ANTIGEN; LEUKOCYTE ANTIGEN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROSTAGLANDIN D2; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BRAIN DAMAGE; BRAIN EDEMA; BRAIN INFARCTION; CELL ACTIVATION; CONTROLLED STUDY; IMMUNOHISTOCHEMISTRY; MICROGLIA; NEUROLOGIC EXAMINATION; NEUROPROTECTION; NONHUMAN; RAT; REPERFUSION INJURY; SPRAGUE DAWLEY RAT; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; METABOLISM; PATHOLOGY;

ANIMALS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; APOPTOSIS; BRAIN EDEMA; BRAIN INFARCTION; DIABETES MELLITUS, EXPERIMENTAL; INTERLEUKIN-1; MICROGLIA; PPAR GAMMA; PROSTAGLANDIN D2; RATS; RATS, SPRAGUE-DAWLEY; REPERFUSION INJURY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84957102934     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/864509     Document Type: Article

References (31)

1. R. C. Turner, B. Lucke-Wold, N. Lucke-Wold et al. , "Neuroprotection for ischemic stroke: moving past shortcomings and identifying promising directions," International Journal of Molecular Sciences, vol. 14, no. 1, pp. 1890-1917, 2013.
2. P. Aggarwal, J. B. Hall, C. B. McLeland, M. A. Dobrovolskaia, and S. E. McNeil, "Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy," Advanced Drug Delivery Reviews, vol. 61, no. 6, pp. 428-437, 2009.
3. A. I. Kelly-Cobbs, R. Prakash, W. Li et al. , "Targets of vascular protection in acute ischemic stroke differ in type 2 diabetes," American Journal of Physiology-Heart and Circulatory Physiology, vol. 304, no. 6, pp. H806-H815, 2013.
4. M. Y. Hassumi, V. J. Silva-Filho, J. C. Campos-Junior et al. , "PPAR-γ agonist rosiglitazone prevents inflammatory periodontal bone loss by inhibiting osteoclastogenesis," International Immunopharmacology, vol. 9, no. 10, pp. 1150-1158, 2009.
5. M. S. Ola, M. I. Nawaz, H. A. Khan, and A. S. Alhomida, "Neurodegeneration and neuroprotection in diabetic retinopathy," International Journal of Molecular Sciences, vol. 14, no. 2, pp. 2559-2572, 2013.
6. G. Li, X. Xu, D. Wang, J. Wang, Y. Wang, and J. Yu, "Microglial activation during acute cerebral infarction in the presence of diabetes mellitus," Neurological Sciences, vol. 32, no. 6, pp. 1075-1079, 2011.
7. A. Y. Lai and K. G. Todd, "Microglia in cerebral ischemia: molecular actions and interactions," Canadian Journal of Physiology and Pharmacology, vol. 84, no. 1, pp. 49-59, 2006.
8. M. Lalancette-Hebert, G. Gowing, A. Simard, C. W. Yuan, and J. Kriz, "Selective ablation of proliferating microglial cells exacerbates ischemic injury in the brain," The Journal of Neuroscience, vol. 27, no. 10, pp. 2596-2605, 2007.
9. K. L. Lambertsen, B. H. Clausen, A. A. Babcock et al. , "Microglia protect neurons against ischemia by synthesis of tumor necrosis factor," The Journal of Neuroscience, vol. 29, no. 5, pp. 1319-1330, 2009.
10. R. Kapadia, J.-H. Yi, and R. Vemuganti, "Mechanisms of antiinflammatory and neuroprotective actions of PPAR-gamma agonists," Frontiers in Bioscience, vol. 13, no. 5, pp. 1813-1826, 2008.
11. J. Culman, Y. Zhao, P. Gohlke, and T. Herdegen, "PPAR-γ: therapeutic target for ischemic stroke," Trends in Pharmacological Sciences, vol. 28, no. 5, pp. 244-249, 2007.
12. N. A. Victor, E. W. Wanderi, J. Gamboa et al. , "Altered PPAR-γ expression and activation after transient focal ischemia in rats," European Journal of Neuroscience, vol. 24, no. 6, pp. 1653-1663, 2006.
13. S.-Y. Xu and S.-Y. Pan, "The failure of animal models of neuroprotection in acute ischemic stroke to translate to clinical efficacy, Medical ScienceMonitor Basic Research, vol. 28, no. 19, pp. 37-45, 2013.
14. S. Takefuji, T. Murase, Y. Sugimura et al. , "Role of microglia in the pathogenesis of osmotic-induced demyelination," Experimental Neurology, vol. 204, no. 1, pp. 88-94, 2007.
15. U.-K. Hanisch and H. Kettenmann, "Microglia: active sensor and versatile effector cells in the normal and pathologic brain," Nature Neuroscience, vol. 10, no. 11, pp. 1387-1394, 2007.
16. C. T. Ekdahl, Z. Kokaia, and O. Lindvall, "Brain inflammation and adult neurogenesis: the dual role of microglia," Neuroscience, vol. 158, no. 3, pp. 1021-1029, 2009.
17. I. Ferrer and A. M. Planas, "Signaling of cell death and cell survival following focal cerebral ischemia: life and death struggle in the penumbra," Journal of Neuropathology and Experimental Neurology, vol. 62, no. 4, pp. 329-339, 2003.
18. S. Faubel and C. L. Edelstein, "Caspases as drug targets in ischemic organ injury," Current Drug Targets: Immune, Endocrine and Metabolic Disorders, vol. 5, no. 3, pp. 269-287, 2005.
19. P. A. Li, Q. P. He, O. Yi-Bing, B. R. Hu, and B. K. Siesjo, "Phosphorylation of extracellular signal-regulated kinase after transient cerebral ischemia in hyperglycemic rats," Neurobiology of Disease, vol. 8, no. 1, pp. 127-135, 2001.
20. A. Bernardo, G. Levi, and L. Minghetti, "Role of the peroxisome proliferator-activated receptor-γ (PPAR-γ) and its natural ligand 15-deoxy-δ 12, 14-prostaglandin J2 in the regulation of microglial functions," European Journal of Neuroscience, vol. 12, no. 7, pp. 2215-2223, 2000.
21. D. V. Chistyakov, S. E. Aleshin, A. A. Astakhova et al. , "Regulation of peroxisome proliferator-activated receptors (PPAR) αand -γ of rat brain astrocytes in the course of activation by tolllike receptor agonists," Journal of Neurochemistry, vol. 134, no. 1, pp. 113-124, 2015.
22. M. T. Heneka and G. E. Landreth, "PPARs in the brain," Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids, vol. 1771, no. 8, pp. 1031-1045, 2007.
23. M. Ricote, A. C. Li, T. M. Willson, C. J. Kelly, and C. K. Glass, "The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation," Nature, vol. 391, no. 6662, pp. 79-82, 1998.
24. C. Giaginis, G. Tsourouflis, and S. Theocharis, "Peroxisome proliferator-activated receptor-γ (PPAR-γ) ligands: novel pharmacological agents in the treatment of ischemia reperfusion injury," Current Molecular Medicine, vol. 8, no. 6, pp. 562-579, 2008.
25. H. Qin, W. Tan, Z. Zhang et al. , "15d-Prostaglandin J2 protects cortical neurons against oxygen-glucose deprivation/ reoxygenation injury: involvement of inhibiting autophagy through upregulation of Bcl-2," Cellular and Molecular Neurobiology, vol. 35, no. 3, pp. 303-312, 2015.
26. C. N. Koyani, W. Windischhofer, C. Rossmann et al. , "15-Deoxy-δ 12, 14-PGJ2 promotes inflammation and apoptosis in cardiomyocytes via the DP2/MAPK/TNFα axis," International Journal of Cardiology, vol. 173, no. 3, pp. 472-480, 2014.
27. S. Chen, C. Liu, X. Wang, X. Li, Y. Chen, and N. Tang, "15-Deoxy-δ 12, 14-prostaglandin J2 (15d-PGJ2) promotes apoptosis of HBx-positive liver cells," Chemico-Biological Interactions, vol. 214, no. 1, pp. 26-32, 2014.
28. H. Ozasa, M. Ayaori, M. Iizuka et al. , "Pioglitazone enhances cholesterol efflux from macrophages by increasing ABCA1/ABCG1 expressions via PPARγ/LXRα pathway: findings from in vitro and ex vivo studies," Atherosclerosis, vol. 219, no. 1, pp. 141-150, 2011.
29. M. Hamblin, L. Chang, H. Zhang, K. Yang, J. Zhang, and Y. E. Chen, "Vascular smooth muscle cell peroxisome proliferatoractivated receptor-gamma mediates pioglitazone-reduced vascular lesion formation," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 31, no. 2, pp. 352-359, 2011.
30. C. J. Pelham, H. L. Keen, S. R. Lentz, and C. D. Sigmund, "Dominant negative PPARγ promotes atherosclerosis, vascular dysfunction, and hypertension through distinct effects in endothelium and vascular muscle," American Journal of Physiology-Regulatory Integrative and Comparative Physiology, vol. 304, no. 9, pp. R690-R701, 2013.
31. M. Ding, A. C. Carrao, R. J. Wagner et al. , "Vascular smooth muscle cell-derived adiponectin: a paracrine regulator of contractile phenotype," Journal of Molecular and Cellular Cardiology, vol. 52, no. 2, pp. 474-484, 2012.